About Empagliflozin API
Therapeutic CategoryOthers
CAS Number
864070-44-0
API Technology
Synthetic
Dose Form
Liquid
Dr Reddy's Development Status
Under Development
Available Regulatory Filing
USDMF, EUDMF, Korea DMF, Canada DMF
Mechanism of Action
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Indication
JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated:
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Related APIs
Empagliflozin
Others
Salcaprozate Sodium (SNAC) (Excipient For Oral Semaglutide)
Others
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!